Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections
出版年份 2022 全文链接
标题
Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections
作者
关键词
-
出版物
JAMA Network Open
Volume 5, Issue 1, Pages e2137277
出版商
American Medical Association (AMA)
发表日期
2022-01-14
DOI
10.1001/jamanetworkopen.2021.37277
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Molecular epidemiology of Escherichia coli causing blood stream infections in a centralized Canadian region: a population-based surveillance study
- (2020) M.S. Holland et al. CLINICAL MICROBIOLOGY AND INFECTION
- Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial
- (2019) Keith S Kaye et al. CLINICAL INFECTIOUS DISEASES
- Population pharmacokinetics and pharmacodynamics of fosfomycin in non–critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli
- (2018) V. Merino-Bohórquez et al. CLINICAL MICROBIOLOGY AND INFECTION
- Global increase and geographic convergence in antibiotic consumption between 2000 and 2015
- (2018) Eili Y. Klein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences
- (2018) Matthew E. Falagas et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model
- (2016) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fosfomycin
- (2016) Matthew E. Falagas et al. CLINICAL MICROBIOLOGY REVIEWS
- Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using anIn VitroInfection Model
- (2015) Brian D. VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance
- (2015) F. Docobo-Pérez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum -lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial
- (2015) C. Rosso-Fernandez et al. BMJ Open
- Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions
- (2012) L. S. Tzouvelekis et al. CLINICAL MICROBIOLOGY REVIEWS
- -Lactam/ -Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum -Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts
- (2011) J. Rodriguez-Bano et al. CLINICAL INFECTIOUS DISEASES
- International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases
- (2011) Kalpana Gupta et al. CLINICAL INFECTIOUS DISEASES
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
- Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review
- (2009) Matthew E Falagas et al. LANCET INFECTIOUS DISEASES
- Clinical significance of extended-spectrum β-lactamases
- (2008) Jesús Rodríguez-Baño et al. Expert Review of Anti-Infective Therapy
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started